Pharma Industry Likely To Take Wait-And-See Approach To GSK U.S. Sales Incentive Changes
Executive SummaryLike the canaries that miners used to take deep into the coal mines with them to ensure the air was of breathing quality, GlaxoSmithKline sales representatives will play a pioneering role starting next year when new compensation practices based not on sales totals but instead on customer service are implemented
You may also be interested in...
Three years into the ACA, the biopharma industry takes stock of its near-term wins and losses as the law’s critical expanded insurance coverage takes effect beginning in 2014. Pharma still isn’t sure whether the increase in covered lives from the exchanges will boost prescription sales enough to offset the rebates, taxes, and fees it agreed to pay out, or what kind of patients constitute this new market.
About a year into GSK’s innovative sales force incentive program, Jack Bailey, head of payers, policy and vaccines, provides an update on the company’s strategy in an interview with “The Pink Sheet” DAILY.
GlaxoSmithKline exec Deidre Connelly and other panelists at the PDR Network’s PharmEHR Summit describe how sales reps can complement the information now available to physicians electronically at the point of prescribing.